Brief: Modus Therapeutics Announces First Patient Enrolled In Phase I Sevusmart Clinical Trial Evaluating Sevuparin In Paediatric Patients With Severe Malaria
01/09/2022 21:26
Sept 1 (Reuters) - Modus Therapeutics Holding AB MODTX.ST :
* MODUS THERAPEUTICS ANNOUNCES FIRST PATIENT ENROLLED IN THE
PHASE
I SEVUSMART CLINICAL TRIAL EVALUATING SEVUPARIN IN PAEDIATRIC
PATIENTS WITH SEVERE MALARIA
Source text for Eikon: ID:nWkrbXkXVm
Further company coverage: MODTX.ST
((Reuters.briefs@thomsonreuters.com;))
Recent news on Modus Therapeutics Holding AB
See all newsBrief: Modus Therapeutics Temporarily Pauses Enrollment In Phase IIa Study Of Sevuparin In CKD With Anemia
Brief: Modus Gets SEK 0.13 Mln Through Exercise Of Warrants
Brief: Modus Therapeutics Resolves On Directed Share Issue Of 20 Million Shares
Sweden's Modus Therapeutics narrows Q2 net loss, extends financing
Brief: Modus Therapeutics Q2 Net Income SEK -4.645 Million